<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35342203</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>20</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>20</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">2472-2448</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>52</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Feb</Month>
              <Day>25</Day>
            </PubDate>
          </JournalIssue>
          <Title>Psychopharmacology bulletin</Title>
          <ISOAbbreviation>Psychopharmacol Bull</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Successful Add-on Viloxazine to Clozapine-Responsive Schizophrenia Mitigated Cognitive, Negative and Metabolic Domains.</ArticleTitle>
        <Pagination>
          <StartPage>57</StartPage>
          <EndPage>60</EndPage>
          <MedlinePgn>57-60</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Early-onset schizophrenia is notorious for poor prognostication and treatment-refractoriness. Clozapine remains a viable option, albeit off-label, but is clearly underutilized in this population. Use is typically fraught with panoply of drastic side effects. Here, authors report on an adolescent case with schizophrenia that responded ultimately to clozapine. Add-on viloxazine was advantageous spanning different symptom domains, mitigating metabolic parameters and addressing clozapine-sialorrhea. This might open new venues for such complicated, yet commonplace, clinical scenarios.</AbstractText>
          <CopyrightInformation>Copyright © 1964–2022 by MedWorks Media Inc, Los Angeles, CA All rights reserved. Printed in the United States.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Naguy</LastName>
            <ForeName>Ahmed</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Naguy, MBBch, MSc, Child/Adolescent Psychiatrist, Al-Manara CAP Centre, Kuwait Centre for Mental Health (KCMH), Jamal Abdul-Nassir St, Shuwaikh, State of Kuwait. Rushdy, MD, PhD, Professor of Psychiatry, Psychiatry Departments, Al-Azhar University, Cairo, Egypt. Pridmore, MD, Professor of Psychiatry, University of Tasmania, Hobart, Australia. Singh, MBBch, MD, Mrcpsych (UK), Speciality Doctor, Learning Disabilities, Exeter, Devon NHS partnership Trust, UK, and Assistant Professor, Psychiatry, Saraswati medical college, Lucknow, India. Alamiri, MD, ABPN, ScD, Consultant Psychiatrist, Chairperson, Al-Manara CAP Centre, KCMH, Kuwait, and Tufts University, Medford, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rushdy</LastName>
            <ForeName>Reda</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Naguy, MBBch, MSc, Child/Adolescent Psychiatrist, Al-Manara CAP Centre, Kuwait Centre for Mental Health (KCMH), Jamal Abdul-Nassir St, Shuwaikh, State of Kuwait. Rushdy, MD, PhD, Professor of Psychiatry, Psychiatry Departments, Al-Azhar University, Cairo, Egypt. Pridmore, MD, Professor of Psychiatry, University of Tasmania, Hobart, Australia. Singh, MBBch, MD, Mrcpsych (UK), Speciality Doctor, Learning Disabilities, Exeter, Devon NHS partnership Trust, UK, and Assistant Professor, Psychiatry, Saraswati medical college, Lucknow, India. Alamiri, MD, ABPN, ScD, Consultant Psychiatrist, Chairperson, Al-Manara CAP Centre, KCMH, Kuwait, and Tufts University, Medford, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pridmore</LastName>
            <ForeName>Saxby</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Naguy, MBBch, MSc, Child/Adolescent Psychiatrist, Al-Manara CAP Centre, Kuwait Centre for Mental Health (KCMH), Jamal Abdul-Nassir St, Shuwaikh, State of Kuwait. Rushdy, MD, PhD, Professor of Psychiatry, Psychiatry Departments, Al-Azhar University, Cairo, Egypt. Pridmore, MD, Professor of Psychiatry, University of Tasmania, Hobart, Australia. Singh, MBBch, MD, Mrcpsych (UK), Speciality Doctor, Learning Disabilities, Exeter, Devon NHS partnership Trust, UK, and Assistant Professor, Psychiatry, Saraswati medical college, Lucknow, India. Alamiri, MD, ABPN, ScD, Consultant Psychiatrist, Chairperson, Al-Manara CAP Centre, KCMH, Kuwait, and Tufts University, Medford, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Singh</LastName>
            <ForeName>Anubhuti</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Naguy, MBBch, MSc, Child/Adolescent Psychiatrist, Al-Manara CAP Centre, Kuwait Centre for Mental Health (KCMH), Jamal Abdul-Nassir St, Shuwaikh, State of Kuwait. Rushdy, MD, PhD, Professor of Psychiatry, Psychiatry Departments, Al-Azhar University, Cairo, Egypt. Pridmore, MD, Professor of Psychiatry, University of Tasmania, Hobart, Australia. Singh, MBBch, MD, Mrcpsych (UK), Speciality Doctor, Learning Disabilities, Exeter, Devon NHS partnership Trust, UK, and Assistant Professor, Psychiatry, Saraswati medical college, Lucknow, India. Alamiri, MD, ABPN, ScD, Consultant Psychiatrist, Chairperson, Al-Manara CAP Centre, KCMH, Kuwait, and Tufts University, Medford, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Alamiri</LastName>
            <ForeName>Bibi</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Naguy, MBBch, MSc, Child/Adolescent Psychiatrist, Al-Manara CAP Centre, Kuwait Centre for Mental Health (KCMH), Jamal Abdul-Nassir St, Shuwaikh, State of Kuwait. Rushdy, MD, PhD, Professor of Psychiatry, Psychiatry Departments, Al-Azhar University, Cairo, Egypt. Pridmore, MD, Professor of Psychiatry, University of Tasmania, Hobart, Australia. Singh, MBBch, MD, Mrcpsych (UK), Speciality Doctor, Learning Disabilities, Exeter, Devon NHS partnership Trust, UK, and Assistant Professor, Psychiatry, Saraswati medical college, Lucknow, India. Alamiri, MD, ABPN, ScD, Consultant Psychiatrist, Chairperson, Al-Manara CAP Centre, KCMH, Kuwait, and Tufts University, Medford, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Psychopharmacol Bull</MedlineTA>
        <NlmUniqueID>0101123</NlmUniqueID>
        <ISSNLinking>0048-5764</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>5I5Y2789ZF</RegistryNumber>
          <NameOfSubstance UI="D014745">Viloxazine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>J60AR2IKIC</RegistryNumber>
          <NameOfSubstance UI="D003024">Clozapine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014150" MajorTopicYN="Y">Antipsychotic Agents</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003024" MajorTopicYN="Y">Clozapine</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012559" MajorTopicYN="Y">Schizophrenia</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014745" MajorTopicYN="Y">Viloxazine</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">clozapine</Keyword>
        <Keyword MajorTopicYN="Y">early-onset schizophrenia</Keyword>
        <Keyword MajorTopicYN="Y">viloxazine</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pmc-release">
          <Year>2023</Year>
          <Month>2</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>28</Day>
          <Hour>5</Hour>
          <Minute>30</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35342203</ArticleId>
        <ArticleId IdType="pmc">PMC8896751</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Kasoff L, Ahn K, Gochman P et al. Strong Treatment Response and High Maintenance Rates of Clozapine in Childhood—Onset Schizophrenia. 
Journal of Child and Adolescent Psychopharmacology
. 2016;26(5):428–435.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4931305</ArticleId>
            <ArticleId IdType="pubmed">26784704</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Naguy A, Solanki APS, Alamiri B. Newly FDA-approved psychotropic agents- a recap. 
Asian Journal of Psychiatry
. 2021;64:102786.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34298485</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Naguy A, Alamiri B, Khraibut B. Weight Loss During Atomoxetine Add-on to Clozapine-Responsive Schizophrenia. 
American Journal of Therapeutics
. 2018;25(6):e774–e775.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29782344</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakanishi S, Kunugi H, Takahashi T. Efficacy of milnacipran for depressive symptoms in schizophrenia spectrum disorders. 
Psychiatry and Clinical Neuroscience
. 2004;58:226–227.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15009832</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamamoto K, Hornykiewicz O. Proposal for noradrenaline hypothesis of schizophrenia. 
Progress in Neuropsychopharmacology and Biological Psychiatry
. 2004;28:913–922.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15363614</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Poyurovsky M, Fuchs C, Pashinian A et al. Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study. 
Psychopharmacology (Berl)
. 2007;192(3):441–448.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17310385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu ML, Lane HY, Lin SK et al. Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances. 
Journal of Clinical Psychiatry
. 2004;65(6):766–771.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15291653</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stern RG, Bellucci D, Cursi-Vogel N et al. Clozapine-induced sialorrhea alleviated by bupropion- a case report. 
Prog Neuropsychopharmacol Biol Psychiatry
. 2009;33(8):1578–1580.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19800381</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
